Monte Rosa Therapeutics Inc
GLUE
View Detailed Chart
15.380USD
-0.290-1.85%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
684.26MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.85%
5 Days
-1.60%
1 Month
-13.35%
6 Months
+105.34%
Year to Date
-1.91%
1 Year
+201.57%
View Detailed Chart
TradingKey Stock Score of Monte Rosa Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Monte Rosa Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 42 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.17.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Monte Rosa Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Monte Rosa Therapeutics Inc Highlights
StrengthsRisks
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Undervalued
The company’s latest PE is -33.08, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 70.11M shares, increasing 1.55% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.25M shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
30.167
Target Price
+92.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Monte Rosa Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Monte Rosa Therapeutics Inc Info
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Ticker SymbolGLUE
CompanyMonte Rosa Therapeutics Inc
CEOWarmuth (Markus)
Websitehttps://www.monterosatx.com/
Related Instruments
-2.10%
-1.92%
+0.49%
+2.48%
+0.58%
-0.88%
-0.98%
-1.24%
-0.51%
-1.96%
-1.02%
+0.34%
-0.19%
-1.55%
-4.56%
0.00%
-0.55%
-2.51%
-2.86%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
66520.740
-355.260 (-0.53%)
275.340
+1.990 (+0.73%)
1994.980
-27.110 (-1.34%)
361.830
-10.280 (-2.76%)
4492.520
+112.460 (+2.57%)
100.609
+7.287 (+7.81%)
1.151
-0.002 (-0.17%)
160.252
+0.465 (+0.29%)
